Articles for author: Russ Cohen

Russ Cohen

Most Popular

Understanding the Recent Legal Setback for Genmab and Its Implications for Investors Understanding the Recent Legal Setback for Genmab and Its Implications for Investors

Monday brought significant legal news for Genmab A/S (NASDAQ: GMAB) as an appeal arbitrator dismissed the biotech company’s bid for additional milestone and royalty payments related to Darzalex (daratumumab). In an SEC filing, Genmab revealed that the appeal arbitrator in its second arbitration under the license agreement with Janssen Biotech Inc, Johnson & Johnson’s (NYSE: ...

Russ Cohen

Most Popular

PACCAR Quarterly Earnings Overview

PACCAR PCAR, a trucking giant, will unveil its fourth-quarter 2023 results tomorrow, before the stock market opens. Analysts predict earnings per share of $2.20 and revenues of $8.18 billion for the quarter. The consensus estimate for PACCAR’s earnings per share has risen by 3 cents in the past seven days, indicating a potential 25% growth ...

Russ Cohen

Most Popular

Alibaba (BABA) Stock: Evaluating Wall Street Analyst Recommendations Alibaba (BABA) Stock: Evaluating Wall Street Analyst Recommendations

Investors frequently turn to analyst recommendations when considering stock transactions, but how much weight should one give these endorsements? Let’s explore Wall Street’s take on Alibaba (BABA) and delve into the reliability of brokerage endorsements as well as strategies for leveraging them. Analyst Recommendations for Alibaba Alibaba currently boasts an average brokerage recommendation (ABR) of ...

Russ Cohen

Most Popular

HW Wainwright Downgrades Aclaris Therapeutics HW Wainwright Downgrades Aclaris Therapeutics After Underwhelming Study Data

ATU Images/The Image Bank via Getty Images HC Wainwright, an investment bank, has recently downgraded Aclaris Therapeutics (NASDAQ:ACRS) to a neutral rating. This decision comes in response to underwhelming data from a Phase 2 study involving the company’s drug ATI-1777, which was being evaluated for the treatment of atopic dermatitis, or AD. According to the ...

Russ Cohen

Most Popular

First Wave BioPharma: Leading the Charge in Celiac Therapy Innovation

James Sapirstein, Chairman, President & CEO of First Wave BioPharma, Inc. FWBI recently shared insights on Benzinga’s All-Access. First Wave BioPharma is dedicated to pioneering non-systemic therapies for gastrointestinal (GI) diseases. The company is pursuing research on numerous revolutionary therapies for GI diseases. You can watch the full interview here. Featured photo by Hans Reniers ...

Russ Cohen

Most Popular

Pfizer, Autodesk, AbbVie and More: Notable Stock Market Highlights from CNBC’s ‘Final Trades’ Notable Stock Market Highlights from CNBC’s ‘Final Trades’

On CNBC’s “Halftime Report Final Trades,” Liz Young of BNY Mellon Investment Management highlighted the Health Care Select Sector SPDR Fund XLV as her final trade. Joshua Brown of Ritholtz Wealth Management selected Pfizer Inc. PFE, which bottomed in the middle of December. At the JPMorgan Healthcare Conference, Pfizer CEO Albert Bourla expressed the company’s ...

Russ Cohen

Most Popular

Three Top Stocks with Impressive Strength Three Top Stocks with Impressive Strength

Market Momentum and Stock Performance Amid a surge in market activity, numerous stocks are approaching or surpassing their 52-week highs. Among the standout performers are household names such as Amazon, Arista Networks, and Abercrombie & Fitch. These companies not only exhibit strong momentum but also hold favorable Zacks Ranks, indicative of upward revisions in earnings ...